propargylic position resemble the sidechain present at the Cα of amino acids. Whereas propargylamines with (cyclo)alkyl substituents can be prepared in a direct manner, residues with polar functional groups require suitable protective groups. The presence of particular functional groups in the sidechain in some cases leads to remarkable side reactions of the alkyne moiety. Thus, electron-withdrawing substituents
A general, enantioselective synthesis of 1-azabicyclo[m.n.0]alkane ring systems
作者:Timothy J. Senter、Michael L. Schulte、Leah C. Konkol、Tyler E. Wadzinski、Craig W. Lindsley
DOI:10.1016/j.tetlet.2013.01.041
日期:2013.3
In this Letter, we describe a novel approach for the general and enantioselectivesynthesis of a diverse array of small to large 1-azabicyclo[m.n.0]alkyl ringsystems with an embedded olefin handle for further functionalization. The stereochemistry is established via a highly diastereoselective indium-mediated allylation of an Ellman sulfinimine in greater than 9:1 dr, which is readily separable by
Total Syntheses of (−) Epilupinine and (−)-Tashiromine Using Imino-Aldol Reactions
作者:Amanda C. Cutter、Iain R. Miller、John F. Keily、Richard K. Bellingham、Mark E. Light、Richard C. D. Brown
DOI:10.1021/ol2015048
日期:2011.8.5
Short routes to enantiomerically pure indolizidine and quinolizidine alkaloids have been developed using imino-aldol reactions of enolates derived from phenyl 5-chlorovalerate. High levels of syn selectivity (dr similar to 13-16:1) were obtained using lithium enolates of phenyl esters In combination with tert-butylsulfinyl imines. The imino-aldol adducts were deprotected and cyclized to afford (-)-epilupinine ((-)-2) and (-)-tashiromine ((-)-1) in two further steps.
WO2020102646A5
申请人:——
公开号:WO2020102646A5
公开(公告)日:2022-11-24
INHIBITORS OF ARG1 AND/OR ARG2
申请人:Arcus Biosciences, Inc.
公开号:US20220016143A1
公开(公告)日:2022-01-20
Compounds that are inhibitors of at least one of ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by ARG1 and ARG2 are also described herein.